Basit öğe kaydını göster

Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.

dc.contributor.authorMorales-Barrera, Rafael
dc.contributor.authorPowles, Thomas
dc.contributor.authorAlva, Ajjai Shivaram
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorO'Donnell, Peter H.
dc.contributor.authorLoriot, Yohann
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorVuky, Jacqueline
dc.contributor.authorPlimack, Elizabeth R.
dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorFradet, Yves
dc.contributor.authorGeczi, Lajos
dc.contributor.authorGunduz, Seyda
dc.contributor.authorMamtani, Ronac
dc.contributor.authorBajorin, Dean F.
dc.contributor.authorLiu, Chih-Chin
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorBellmunt, Joaquim
dc.contributor.authorBalar, Arjun Vasant
dc.date.accessioned2022-07-04T15:50:49Z
dc.date.available2022-07-04T15:50:49Z
dc.date.issued2022
dc.identifier.citationPowles T., Alva A. S. , Ozguroglu M., O'Donnell P. H. , Loriot Y., Csoszi T., Vuky J., Morales-Barrera R., Plimack E. R. , Matsubara N., et al., "Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.", JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.6, 2022
dc.identifier.issn0732-183X
dc.identifier.otherav_c6073dd8-26a2-4f3d-9f32-28b1a596fd3a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/184612
dc.identifier.urihttps://doi.org/10.1200/jco.2022.40.6_suppl.519
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titlePost hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume40
dc.identifier.issue6
dc.contributor.firstauthorID3405540


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster